Novo Nordisk A/S (NVO) Stock News

Novo Nordisk provides weekly update on share buyback programme.

The FDA is continuing its review of Novo Nordisk's Biologics License Application for denecimig, a treatment for haemophilia A. No decision has been announced.

report claims Novo Nordisk's semaglutide 2 mg dose reduced the risk of serious cardiovascular events by 6%. No study details or confirmation are available.

Novo Nordisk will pay $300 million upfront for global rights to Hengrui's HRS-1596. The deal could be worth up to $2.6 billion with milestones.

Novo Nordisk provides weekly update on share repurchase programme.

Novo Nordisk Series B rises 0.3%, outperforms weaker Nordic market.

Novo Nordisk open to direct NYSE listing, CEO tells FT.

Deutsche Bank cut its price target on Novo Nordisk to DKK 245 from DKK 265, reflecting a more cautious outlook.

Novo Nordisk's long-term pipeline plan fails to impress investors, lacks near-term targets

Novo Nordisk CEO identifies liver disease and cardiovascular as key expansion areas despite recent setbacks.

Novo Nordisk CEO stated 7 million US prescriptions have been written for the Wegovy pill and that the company recently gained meaningful market share. He also committed to strengthening diabetes care.

Novo Nordisk and Anthropic partner on AI-driven drug development

Novo Nordisk is shortening its public brand to simply "Novo." The move comes alongside a company-wide cultural reset as obesity-drug competition heats up.

Semaglutide showed no new safety concerns in a pediatric study, supporting its use in children.

Deutsche Bank analysts downgraded Novo Nordisk to sell and lowered the price target to DKK 265 from DKK 290. No rationale was provided in the initial report.

Upgrades and downgrades: AVAL, ENTG, IEX, ISRG, JOYY, MRK, OKTA up; APGE, ATAI, CRDF, GAP, LEGN, NVO, ONON, TME down.